FDA grants de novo approval to Neuromod’s tinnitus device

Global News

The FDA has granted de novo approval to Neuromod’s Lenire device, which includes Bluetooth headphones, a handheld controller and the Tonguetip intraoral device to treat tinnitus.

The device is non-invasive and the company claims it is the first of its kind to receive this sort of approval from the FDA. The device combines acoustic and electrical intraoral stimulation to provide relief to patients suffering with tinnitus, which is a complex neurological condition.

The therapy includes three elements: Bluetooth headphones to deliver customised sound stimuli to the auditory nerve; a lightweight, handheld controller, which lets patients adjust the length and intensity of treatment; and an intraoral device known as Tonguetip, which provides gentle electrical stimulation to the surface of the tongue to activate the patient’s nerves.

The sounds and tongue stimulation are intended to work alongside each other to reduce the severity of the patient’s symptoms. The device is the first non-invasive bimodal neuromodulation tinnitus treatment device, which has appeared to relieve tinnitus throughout three large-scale clinical trials.

Neuromod Devices founder and CEO, Ross O’Neill commented: “Lenire’s approval not only means that millions of Americans living with tinnitus can get the treatment they need but further validates over a decade of R&D that resulted in a safe solution that provides relief for tinnitus patients. […] Lenire is the first bimodal neuromodulation device to go through the rigours of the FDA’s de novo process. […] For patients that are at least moderately impacted by their tinnitus, Lenire has now been shown to be more effective than sound therapy, which is one of the current clinical standards of treatment.”

Companies showcase innovative biotech at American Association for Cancer Research

Leading companies in the biotechnology sector have showcased their latest innovations at the American Association for Cancer Research (AACR) meeting that was held in Florida, US, between 14-19 April. The three companies below are a selection of those with positive improvements in solid-tumour treatments.

FDA approves world’s first RSV vaccine

The US Food and Drug Administration (FDA) has announced that it has approved the world’s first respiratory syncytial virus (RSV) vaccine for use in the US in individuals aged 60 or over.

FDA issues update around changes to COVID-19 vaccines’ EUAs

The FDA has announced its amendment of the emergency use authorisations (EUAs) for the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines in an attempt to simplify the vaccination programme.

Johnson & Johnson warns of dangers of Benadryl TikTok challenge

Following the death of a 13-year-old boy who took part in an online ‘challenge’ to take a large amount of the antihistamine, Benadryl (diphenhydramine), manufacturer Johnson & Johnson (J&J) has issued a statement warning of the dangers of overdosing with the drug.

Liberal states begin stockpiling abortion medications following Texas court ruling

Various liberal US states, including California and Massachusetts, have begun stockpiling abortion medications following Texas judge Matthew Kacsmaryk’s attempt to invalidate the long-standing approval of mifepristone, one of the pills used in medication abortions.

Companies showcase innovative biotech at American Association for Cancer Research

FDA approves world’s first RSV vaccine

FDA issues update around changes to COVID-19 vaccines’ EUAs

Johnson & Johnson warns of dangers of Benadryl TikTok challenge

Liberal states begin stockpiling abortion medications following Texas court ruling

Pharmafocus

Categories

Social Footprints